Abbott Laboratories $ABT Shares Acquired by Cetera Investment Advisers

Cetera Investment Advisers boosted its holdings in Abbott Laboratories (NYSE:ABT) by 6.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 408,841 shares of the healthcare product maker’s stock after acquiring an additional 24,027 shares during the period. Cetera Investment Advisers’ holdings in Abbott Laboratories were worth $55,606,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Meridian Wealth Management LLC lifted its position in Abbott Laboratories by 6.8% in the second quarter. Meridian Wealth Management LLC now owns 15,318 shares of the healthcare product maker’s stock valued at $2,083,000 after buying an additional 977 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of Abbott Laboratories by 7.6% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 426,704 shares of the healthcare product maker’s stock valued at $58,036,000 after acquiring an additional 30,056 shares during the period. Foundations Investment Advisors LLC lifted its holdings in shares of Abbott Laboratories by 3.6% in the 2nd quarter. Foundations Investment Advisors LLC now owns 10,841 shares of the healthcare product maker’s stock worth $1,475,000 after acquiring an additional 377 shares during the last quarter. CFO4Life Group LLC increased its holdings in Abbott Laboratories by 4.2% in the 2nd quarter. CFO4Life Group LLC now owns 2,300 shares of the healthcare product maker’s stock valued at $313,000 after purchasing an additional 93 shares during the last quarter. Finally, RAM Investment Partners LLC raised its position in Abbott Laboratories by 58.5% in the second quarter. RAM Investment Partners LLC now owns 6,345 shares of the healthcare product maker’s stock valued at $863,000 after purchasing an additional 2,343 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ABT shares. Mizuho lifted their price objective on Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, October 14th. BTIG Research reiterated a “buy” rating and set a $145.00 price target on shares of Abbott Laboratories in a research note on Wednesday, October 15th. Evercore ISI lowered their price objective on shares of Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating for the company in a research note on Wednesday, October 15th. Daiwa Capital Markets increased their target price on shares of Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a report on Tuesday, October 21st. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $147.00 target price on shares of Abbott Laboratories in a research note on Thursday, October 16th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $147.00.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $130.59 on Friday. The stock’s 50-day moving average is $130.38 and its two-hundred day moving average is $131.35. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23. The firm has a market cap of $227.08 billion, a price-to-earnings ratio of 16.36, a PEG ratio of 2.36 and a beta of 0.68.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.30. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The firm had revenue of $11.37 billion during the quarter, compared to analysts’ expectations of $11.40 billion. During the same period in the prior year, the firm earned $1.21 EPS. The business’s revenue was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.